Financings

Acylin Pharmaceuticals Inc. raised an undisclosed amount of Series A funding to target acetylation.

Anacor Pharmaceuticals Inc. raised $60 million in its IPO and $10 million in a private placement.

Bavarian Nordic A/S raised $36.2 million in a private placement of stock.

BG Medicine Inc. plans to sell 4.75 million shares for $13 to $15 each in its IPO, raising $67 million.

BioTheryX Inc. got an undisclosed amount of equity funding from the Leukemia & Lymphoma Society.

PharmAthene Inc. raised $14. 1 million in its previously announced public stock offering.

PhaseBio Pharmaceuticals Inc. added $15 million to its Series B financing.

Regenesance BV raised an undisclosed amount of seed funding for preclinical complement research.

SuppreMol GmbH raised $20.3 million in Series C financing.

Theravance Inc. is raising $129.3 million in a private stock placement with partner GlaxoSmithKline plc.

ThromboGenics NV is raising $46.3 million in a private placement.

Deals

Ascenta Therapeutics Inc. partnered with Ascentage Pharma Group Corp. Ltd. on two cancer drugs.

AVEO Pharmaceuticals Inc. got $25 million in an expanded discovery deal with Astellas Pharma Inc.

Axcan Holdings Inc. is acquiring Eurand NV for $583 million.

Galenica AG teamed up with Fresenius Medical Care AG & Co. KGaA on a new renal drug company.

Insmed Inc. and Transave Inc. are merging in a stock swap

SmartCells Inc. is being acquired by Merck & Co. Inc. for $500 million.

. . . And More

Amarin Corp.'s AMR101 (ethyl icosapentate) lowered triglycerides but not LDL-C in Phase III.

Basilea Pharmaceutica AG got $130 million in arbitration from ceftobiprole partner Johnson & Johnson.

Icagen Inc.'s stock jumped 78 percent when partner Pfizer Inc. selected a lead pain candidate.

Keryx Biopharmaceuticals Inc.'s Zerenex (ferric citrate) met its endpoints in a Phase III dialysis trial.

NanoBio Corp. won a $6 million grant for an intranasal respiratory syncytial virus vaccine.

Valeant Pharmaceuticals International Inc. and GlaxoSmithKline plc got a complete response letter for epilepsy drug ezogabine.